Modality
Gene Editing
MOA
VEGFi
Target
APOC3
Pathway
Ferroptosis
Asthma
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ May 2028
Phase 2Current
NCT07658404
1,933 pts·Asthma
2022-08→2028-05·Active
1,933 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-212.1y awayPh2 Data· Asthma
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Active
Catalysts
Ph2 Data
2028-05-21 · 2.1y away
Asthma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07658404 | Phase 2 | Asthma | Active | 1933 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |